Related Experiment Video

Updated: Aug 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Treatment with Miltex for metastatic skin lesions in breast cancer]

V M Moĭseenko1, R V Orlova, N A Ermakova

  • 1N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.

Voprosy Onkologii
|February 24, 2001
PubMed

Insights

Miltex (miltefosine) shows promise for treating metastatic breast cancer skin lesions. In a small trial, it achieved partial regression in over 27% of patients with moderate, manageable side effects.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Metastatic breast cancer often involves skin lesions.
  • Standard therapies may not be effective for all patients.
  • Topical treatments offer a localized approach.

Purpose of the Study:

  • To evaluate the efficacy and safety of Miltex (miltefosine) for topical treatment of metastatic breast cancer skin lesions.
  • To assess therapeutic response in patients resistant to standard treatments.

Main Methods:

  • A clinical trial involving 11 breast cancer patients with metastatic skin lesions.
  • Patients were resistant to standard cancer therapies.
  • Topical application of Miltex (miltefosine).

Main Results:

  • A partial regression of skin lesions was observed in 27.3% (3/11) of patients.
  • The most common side effects included skin itching (36.4%), paper skin (45.5%), and erythema (18.2%).

Conclusions:

  • Miltex (miltefosine) demonstrates potential as a topical therapy for metastatic breast cancer skin lesions.
  • The drug was generally well-tolerated, with moderate, localized side effects.

More Related Videos

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...